# Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

> **NCT00960479** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 38 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
- **DRUG:** Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)

## Key facts

- **NCT ID:** NCT00960479
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2001-02
- **Final completion:** 2001-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960479, "Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00960479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*